TO THE EDITOR
The efficacy of arsenic trioxide (ATO) in relapsed patients with acute promyelocytic leukemia (APL) has been established. ATO can be used as a single agent and induces complete remission with only minimal myelosuppression. Several reports showed that 80-85% of relapsed APL patients achieved complete remission with ATO alone. The 18-month overall survival was 42-66%. 1, 2 The most important adverse event with ATO therapy is prolongation of the QT/QTc interval on ECG. This event was reportedly observed in 40-93% of ATO-administered patients and was occasionally accompanied with ventricular tachycardia including torsades de pointes. 3, 4 In hematological toxicity, however, only leukocytosis during ATO-induction therapy was reported.
1,2 Furthermore, the effect of ATO therapy on normal hematopoiesis has not been carefully analyzed.
From 1999 to 2004, we experienced nine APL patients who had been treated with ATO as a phase II study of ATO therapy for relapsed APL patients at Nagoya University Hospital. All patients relapsed after ATRA and conventional chemotherapy. For induction therapy, treatment (0.15 mg/kg daily) was discontinued before day 60 if the patients had achieved bone marrow remission or if substantial toxicity was observed. Patients who had achieved complete remission were treated with subsequent two consolidation therapies (0.15 mg/kg daily 
Figure 1
Clinical course of patient 4. Severe neutropenia and remarkable increase of reticulocyte and Epo were observed. Progression of anemia and thrombocytepenia were mild (ATO, arsenic trioxide; WBC, white blood cell; RBC, red blood cell; Plt, platelets; Ret, reticulocyte; Epo, erythropoietin).
for 28 days) after 3-6-week intervals. Eight achieved complete remission and seven had consolidation therapy with ATO. In seven patients, only case 1, as PML-RARa was positive by RT-PCR after the second course of consolidation therapy, received four more courses of ATO consolidation therapy (shown in Table 1 ).
A typical clinical course is shown in Figure 1 . Although the white blood cell (WBC) count decreased during ATO consolidation therapy, little change was observed in red blood cell (RBC). The reticulocyte count increased during ATO consolidation therapy, and without the therapy, it decreased to the normal range. Similar to reticulocytes, the serum erythropoietin (Epo) concentration increased during the treatment and then decreased. During therapy, no signs of hemolysis such as erythrocyte destruction, decreased haptoglobin, increased indirect bilirubin and LDH were observed.
The CBC data in 17 courses of ATO consolidation are shown in Figure 2 . The examinations were performed 1 or 2 days before ATO consolidation (before) and on the last day or the day before the last day of ATO consolidation (after). After ATO treatment, reticulocytes increased in all seven patients (Po0.0001). In addition, the serum concentration of Epo also increased in all 7 patients, in 10 courses examined (shown in Figure 3a , P ¼ 0.0024). These data suggest that the increase of reticulocytes depends on the increase of Epo concentration. On the other hand, WBC and neutrophils remarkably decreased after therapy (Po0.0001). RBC slightly decreased during therapy (P ¼ 0.011); increased with five courses in three patients and decreased with 12 courses in seven patients. Reticulocytes increased in both groups (increased: P ¼ 0.046; decreased: Po0.0001). Thrombocytes showed little change during therapy (P ¼ 0.62).
These clinical findings suggest that ATO can induce the expression of Epo. To study this mechanism, we used a human hepatoma cell line, Hep3B, in which Epo production is markedly increased after exposure to hypoxia or cobalt chloride (CoCl 2 ). 5 We investigated the effect of ATO on the mRNA expression of Epo in Hep3B cells using real-time PCR examination. In an atmosphere of 20% O 2 , the expression of Epo mRNA increased up to seven times in a therapeutic concentration (0.5 mM) of ATO treatment for 24 h. On the other hand, with a higher concentration (2.5 mM) of ATO, cell growth was inhibited at this concentration, and the expression of Epo decreased to the baseline (Figure 3b ). These findings suggest that Epo is directly induced by ATO in APL patients.
Using Hep3B and HepG2 cell lines, it was reported that expression of Epo regulated by a major transcriptional factor, hypoxia inducible factor 1, HIF-1.
6,7 HIF-1 is a basic helix-loophelix transcription factor, composed of two subunits, HIF-1a and HIF-1b HIF-1b is constitutively expressed, whereas HIF-1a expression is increased upon hypoxia or in response to CoCl 2 . In normoxia, HIF-1a is rapidly ubiquitinated by the von hippellindau tumor suppressor E3 ligase complex and subjected to proteasomal degradation. Under hypoxic conditions, the degradation of HIF-1a is suppressed, and accumulates to form an active complex with HIF-1b. This activated HIF-1 complex binds at the Epo enhancer, resulted in increase of Epo expression. 6 We therefore investigated the protein level of HIF-1a by Western blotting analysis. As shown in Figure 3c , a remarkable increase of HIF-1a protein was detected in CoCl 2 -treated Hep3B, and a moderate increase of HIF-1a protein was detected in ATO-treated Hep3B. These results suggest that ATO increased protein level of HIF-1a resulting in Epo expression in Hep3B cells. Some reports showed that the Epo gene is negatively regulated under normoxic conditions by GATA-2, which binds to the GATA site of the Epo promoter in Hep3B cells. 8 We investigated the expression of GATA-2 in Hep3B, but no difference was observed between ATO-treated and nontreated Hep3B (data not shown). These results suggest that ATO increases Epo expression by modulating the expression of HIF-1a.
While RBC increased with five courses in three patients and decreased with 12 courses in seven patients, the reticulocyte count increased in all courses. These results suggest that the increase of reticulocytes during therapy is a reaction to the increase of Epo concentration but not to anemia. Despite the increased Epo and reticulocytes, polycythemia was not observed in patients with ATO. In bone marrow, erythroblasts increased and megaroblastic change was often observed (date not shown). No evidence of hemolysis and blood loss was detected in these patients. These results suggest that dyserythropoiesis may also exist in ATO-treated patients. Further studies should be performed to clarify the details of erythropoiesis in ATO-treated patients. Medicine, Nagoya University, Showa-ku, Nagoya, Japan
Figure 3
Serum concentration of Epo in the patients with ATO consolidation therapy (a). The concentration of Epo was measured using a radioimmune assay in the SRL laboratory (Tachikawa, Japan). The serum concentration of Epo increased in all patients and in all courses examined (P ¼ 0.0024). Epo mRNA expression level in Hep3B cell line using RQ-PCR (b). Total RNA was obtained from Hep3B cells which were treated with or without ATO and hypoxia (1% O 2 ) using RNA STAT-60 (Tel-Test Inc., Friendswood, TX, USA). One microgram of total RNA was transcribed into cDNA using MuLV-reverse transcriptase (Applied Biosystems, Foster city, CA, USA) at 421C for 1 h in a total volume of 40 ml containing 0.1 nmol Random Hexamers (Applied Biosystems), 1 mM of each dNTP, 100 U of MuLV-reverse transcriptase (Applied Biosystems), 40 U of RNase Inhibitor, 1 Â buffer (50 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 mM MgCl 2 ). At the end of incubation, the reaction mixture was heated to 701C for 10 min. The expression level of Epo transcript was quantified by a real-time fluorescence detection method on an ABI Prism 7000 sequence detection system using Assays-on-Demand Gene Expression products (Applied Biosystems). The housekeeping gene, GAPDH, was used as a control for cDNA quality. Relative gene expression levels were calculated using standard curves and adjusted based on the expression level of the GAPDH gene. Each gene expression level was analyzed in triplicate and the mean was subjected to analysis. Western blotting analysis for HIF-1a in Hep3B cell line (c). In all, 20 mg of nuclear extracts from Hep3B cells were used for each lane. Upper panel indicates HIF-1a protein expression. Lower panel shows histone H3 as a loading control. A representative result of three independent experiments with consistent results is shown (Cont, no treat; ATO, the cells were treated with 0.5 mM ATO for 24 h; Co, the cells were treated with 100 mM CoCl 2 for 1 h).
